A groundbreaking pan-Canadian research effort has introduced a circulating tumor DNA (ctDNA) blood test for Fibroblast Growth Factor Receptor (FGFR) alterations, significantly broadening access to targeted therapies for patients with metastatic urothelial cancer (mUC). This innovation, detailed in a recent Nature Communications publication, addresses longstanding barriers in traditional tissue biopsy testing and promises to transform precision oncology across Canada.
Understanding Metastatic Urothelial Cancer in Canada
Metastatic urothelial cancer, primarily affecting the bladder but also the ureters and renal pelvis, represents the advanced stage of urothelial carcinoma (UC), the most common type of bladder cancer. In Canada, bladder cancer is diagnosed in approximately 12,600 individuals annually, with around 9,500 cases in men and 3,100 in women, making it the fifth most common cancer overall and fourth among men. About 2,500 Canadians die from it each year. While early-stage disease is often manageable, mUC has a poor prognosis, with five-year survival rates below 15 percent due to its aggressive spread to distant organs like the lungs, liver, and bones.
Risk factors include smoking (responsible for half of cases), occupational exposures to chemicals, and chronic bladder irritation. Treatment typically involves platinum-based chemotherapy, but upon progression, options are limited until targeted therapies emerged. FGFR alterations—genetic changes in FGFR2 or FGFR3 genes that drive uncontrolled cell growth—occur in 20 to 30 percent of mUC cases globally and similarly in Canada, positioning them as key biomarkers for precision medicine.
Limitations of Traditional Tumor Tissue Testing
Standard FGFR testing relies on tumor tissue biopsies analyzed via next-generation sequencing (NGS) or other genomic assays. While effective, this approach faces challenges: obtaining fresh tissue from metastatic sites is invasive, risky for frail patients, and often yields insufficient material—up to 30 percent of samples fail. Moreover, tumors are heterogeneous, meaning a single biopsy may miss FGFR alterations present elsewhere, especially as cancer evolves post-treatment. In Canada, variability in testing protocols across provinces further complicates equitable access.
These hurdles delay therapy initiation, with erdafitinib (Balversa), Canada's first approved FGFR-targeted therapy since 2020 for platinum-refractory FGFR3-altered mUC, requiring confirmed alterations for eligibility. Health Canada approved it based on trials showing 40 percent objective response rates and median progression-free survival of 5.5 months.
The Rise of Liquid Biopsy: ctDNA Blood Testing Explained
Circulating tumor DNA (ctDNA) testing, or liquid biopsy, detects tumor-derived DNA fragments shed into the bloodstream. This non-invasive blood draw captures a comprehensive genomic snapshot from all metastatic sites, overcoming tissue limitations. For FGFR, ctDNA assays target hotspot mutations and fusions in FGFR3 using ultrasensitive digital droplet PCR (ddPCR) or NGS panels.
The process is straightforward: a simple venipuncture yields plasma, from which ctDNA is extracted and sequenced. Results return in days, enabling rapid therapy decisions. Serial testing monitors treatment response, resistance emergence, and minimal residual disease, revolutionizing dynamic cancer management.
Pan-Canadian Study: Methods and Groundbreaking Results
Led by Dr. Bernhard J. Eigl, director of BC Cancer's Provincial Clinical Trials Office, and Dr. Alexander W. Wyatt, scientific director of the Cancer Genetics and Genomics Laboratory at the Vancouver Prostate Centre (University of British Columbia), this prospective multicenter study profiled plasma ctDNA from 208 mUC patients routinely undergoing tissue FGFR testing for erdafitinib eligibility.
Key results: FGFR alterations detected in 26 percent via ctDNA or tissue—aligning with expected prevalence. In 125 paired samples, concordance reached 90 percent, with ctDNA sensitivity at 84 percent for tissue positives. Crucially, ctDNA identified seven additional FGFR-positive cases missed by tissue, likely due to heterogeneity or sample inadequacy. Serial draws post-baseline provided real-time evolution insights.
| Metric | ctDNA Testing | Tissue Testing |
|---|---|---|
| FGFR+ Detection Rate | 26% | 26% |
| Paired Concordance (n=125) | 90% | - |
| Sensitivity for Tissue+ | 84% | - |
| Additional Positives Found | 7 | 0 |
Clinical Impact: Erdafitinib Outcomes and Patient Stories
Of 21 study patients receiving erdafitinib post-testing, median progression-free survival was 7.5 months—consistent with pivotal trials. Notably, one patient with ctDNA-exclusive FGFR detection achieved 33 months on therapy, underscoring ctDNA's value. "Identifying FGFR alterations via ctDNA when tissue testing failed means we can provide active therapies patients could otherwise not access," says Dr. Eigl. "These treatments have a meaningful survival impact."
Erdafitinib, an oral pan-FGFR tyrosine kinase inhibitor, blocks aberrant signaling, shrinking tumors in responsive patients while managing side effects like hyperphosphatemia through dosing adjustments.
Pan-Canadian Collaboration: Universities and Centers United
This effort exemplifies Canada's research ecosystem, uniting 12 sites: BC Cancer (Vancouver, Kelowna, Abbotsford, Victoria, Surrey), University of Calgary's Arthur J.E. Child Cancer Centre, Cross Cancer Institute (U Alberta), Ottawa Hospital Research Institute (uOttawa), Princess Margaret Cancer Centre (U Toronto), CHU de Québec-Université Laval, London Health Sciences Centre (Western U), and Lady Davis Institute (McGill). PhD student Andrew Murtha, co-first author from UBC, highlights early-career involvement funded by BC Cancer Foundation.
- Overcomes provincial silos for standardized testing.
- Leverages academic labs for assay development.
- Paves way for national ctDNA guidelines.
Broader Implications for Precision Oncology and Patient Care
By expanding the eligible pool—potentially 20-30 percent more patients—this test reduces biopsy burdens, accelerates erdafitinib access, and cuts costs. In Canada's universal healthcare, equitable precision medicine is vital; ctDNA bridges urban-rural gaps. For the ~3,200 treated la/mUC patients yearly, even modest uptake could extend lives.
Stakeholders praise: "Cancer evolves; ctDNA captures that," notes Dr. Wyatt. Patients gain hope, oncologists tools, researchers data for trials.
Challenges, Solutions, and Future Directions
Challenges include ctDNA assay standardization, reimbursement (pCODR reviewing erdafitinib companions), and false negatives in low-burden disease. Solutions: validate across labs, integrate AI for sensitivity, pair with imaging.
Next: BC-wide clinical ctDNA rollout via Wyatt's lab; national trials via CCTG; expand to other biomarkers (e.g., NTRK). With Canada's genomics leadership, routine liquid biopsies loom.
For more on the study, see the full Nature Communications paper.
Stakeholder Perspectives and Real-World Cases
Oncologists like Dr. Srikala Sridhar (U Toronto) emphasize speed: "Days vs. weeks for biopsy." Patients report less anxiety sans procedures. Case: A BC patient, tissue-negative, ctDNA-positive, now 33 months stable.
Actionable Insights for Researchers and Clinicians
- Prioritize paired ctDNA-tissue in mUC workups.
- Serial ctDNA for resistance monitoring.
- Advocate provincial funding.
- Collaborate via CanCORD networks.
This pan-Canadian FGFR blood test heralds a new era, blending academic innovation with clinical impact for better mUC outcomes nationwide. Bladder cancer patients stand to benefit immensely from this timely advance.
